Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow LFVN by emailGet an email when LFVN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LFVN, unsubscribe in one click. Privacy
📣 What LFVN Says Is Next
Fourth Quarter · “We intend to move forward with a real sense of urgency and look forward to sharing more about our strategy as our work progresses." Fourth Quarter Fiscal 2026 Results For the fourth quarter ended June 30, 2026, the Company reported revenue of $42.4 million, a 23.1% decrease compared to revenue of $55.1 million in the fourth quarter of fiscal 2025.”
Company press release, Aug 27, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full LFVN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LFVN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.